A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

NCT05662020 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

2750

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Papillomavirus Infection

Interventions

BIOLOGICAL: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
BIOLOGICAL: GARDASIL® 9

Sponsor

Beijing Health Guard Biotechnology, Inc

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]